The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Pharmacokinetic and pharmacodynamic studies on high doses of fluphenazine
Abstract
Six chronic schizophrenics--earlier refractory to recommended doses of neuroleptic drugs but eventually responding to 250 mg fluphenazine heptanoate weekly--participated in a pharmacokinetic study. Five out of the six patients showed rather constant steady state plasma fluphenazine values on a 250 mg depot weekly. After depot drug withdrawal, the single oral dose pharmacokinetics on 400 mg fluphenazine showed the same variations in Cmax, tmax, t 1/2 and AUC as are observed when recommended doses of fluphenazine are used. We thus could not demonstrate any dose-dependent pharmacokinetics on high oral fluphenazine doses. In half the patients, a biphasic decay in the plasma concentration curve indicated at least two compartments. The patients were then studied for up to 2 years on 200-500 mg fluphenazine as a single daily dose. The fluphenazine plasma levels were rather constant in the individual patients during this period. The plasma prolactin values were related to the fluphenazine values even in the high value area, thus showing a persistent pharmacodynamic variation capacity. The clinical part of the study did not show any relevant findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fluphenazine decanoate is the only commercially available LAI formulation of the phenothiazine fluphenazine [48, 49].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [48]
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE
Åsberg, M., Montgomery, S., Perris, C., Schalling, D., & Sedvall, G. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb02357.x · Cited by 1,327
CSTRIP, a Fortran IV Computer Program for Obtaining Initial Polyexponential Parameter Estimates
Sedman, A. J., & Wagner, J. G. (1976) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600650713 · Cited by 322
Drug-induced extrapyramidal disorders.
Chase, T. N. (1972) · PubMed · Cited by 104
Curry, S., Whelpton, R., de Schepper, P., Vranckx, S., & SCHIFF, A. A. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb00941.x · Cited by 84
High doses of fluphenazine enanthate in schizophrenia: A CONTROLLED STUDY
Dencker, S. J., Johansson, R., Lundin, L. B., & Malm, U. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb06909.x · Cited by 31
Self-citationAndersen, K., Malm, U., Perris, C., Rapp, W., & Román, G. (1974) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1974.tb08042.x · Cited by 24
Self-citationKinetics of oral fluphenazine disposition in humans by GC-MS
Midha, K. K., McKay, G., Edom, R., Korchinski, E. D., Hawes, E. M., & Hall, K. E. (1983) · European Journal of Clinical Pharmacology · doi:10.1007/bf00542363 · Cited by 22
Wiles, D., Franklin, M., Dencker, S. J., Johansson, R., Lundin, L. B., & Malm, U. (1980) · Psychopharmacology · doi:10.1007/bf00434400 · Cited by 19
Self-citation
Cited by
Sorted by citations
Correll, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205
Distribution of Fluphenazine and Its Metabolites in Brain Regions and Other Tissues of the Rat
Aravagiri, M., Marder, S. R., Yuwiler, A., Midha, K. K., Kula, N. S., & Baldessarini, R. J. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00070-t · Cited by 38
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Sampford, J., Sampson, S. J., Li, B. G., Zhao, S., Xia, J., & Furtado, V. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010832.pub2 · Cited by 14
Fluphenazine decanoate (timing of administration) for people with schizophrenia
Abbas, F., Rajab, T. M., Alsamarrai, O., Alhalabi, N., Addeen, S. Z., Mheish, O., Aljojo, A., & Essali, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012810 · Cited by 3
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Sampford, J., & Sampson, S. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010832 · Cited by 3
Brown, A. R., Trznadel, M., Pedersen, S., Perkins, A. N., Lee, M., Mohutsky, M. A., Bell, A., Pihlaja, T. L. M., Sikanen, T. M., Weil, M., et al. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.5c15513 · Cited by 2
Bedeutung der Pharmakokinetik für die neuroleptische Behandlung am Beispiel von Fluphenazin
Breyer-Pfaff, U. (1990) · Springer eBooks · doi:10.1007/978-3-642-93466-7_3 · Cited by 1
Metadata
- Authors
- Dencker, S. J., Johansson, R., & Malm, U.
- ORCID
- Malm, U.
- Venue
- Psychopharmacology
- Published
- 1988-02
- Volume
- 94
- Issue
- 2
- Pages
- 237-41
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2087147840
- Cited by
- 7
- References
- 11
- Citations by year
- 2026: 1 · 2021: 1 · 2017: 1 · 2016: 1 · 2013: 1
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- fluphenazine, pharmacokinetics, pharmacodynamics, chronic schizophrenia, refractory schizophrenia, plasma prolactin, nonlinear pharmacokinetics, steady-state plasma concentration, antipsychotic treatment response
- MeSH terms
- Adult, Female, Fluphenazine, Humans, Male, Middle Aged, Prolactin, Schizophrenia, Schizophrenic Psychology, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
